Regulus Therapeutics reported $-6719000 in Net Income for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Alnylam Pharmaceuticals ALNY:US $ -277.4M 37.06M
AstraZeneca AZN:LN 360M 26M
Astrazeneca AZN:US $ 360M 26M
Biogen BIIB:US $ 1058M 754.2M
Celldex Therapeutics CLDX:US $ -23.05M 2.9M
Gilead Sciences GILD:US $ 1144M 1125M
GlaxoSmithKline GSK:LN 838M 964M
Intercept Pharmaceuticals ICPT:US $ -7.53M 9.76M
Intrexon XON:US $ -19.25M 5.78M
Lexicon Pharmaceuticals LXRX:US $ -24.59M 1.11M
Ligand Pharmaceuticals LGND:US $ -15.38M 9.97M
Merk MRK:US $ 3944M 366M
Regulus Therapeutics RGLS:US $ -6.72M 0.41M
Spectrum Pharmaceuticals SPPI:US $ -15.44M 24.27M
Takeda 4502:JP Y 105014M 116372M
Vital Therapies VTL:US $ -20.81M 0.38M
YTE INCY:US $ 161.43M 123.44M